RealFeedApp Two trial participants died
After two participant deaths in a Phase 2a trial for autoimmune diseases, Artiva Biotherapeutics has announced the end of its AlloNK natural killer cell therapy development and major staff cuts. One death was linked to fludarabine chemotherapy, while the cause of the second death is still being investigated.
- Field
- medicine and diagnostics
- What they did
- Artiva Biotherapeutics is stopping development of its experimental natural killer cell therapy (AlloNK) for autoimmune conditions after two trial participants died.
- Why it matters
- The company reported these deaths occurred during Phase 2a trials for inflammatory diseases like rheumatoid arthritis, though investigators concluded the deaths were likely caused by other treatment components or remain undetermined.
#cell therapy#clinical trial#safety#nk cells#autoimmune
